Revamped Cancer Drugs Fund launched in England

A revised Cancer Drugs Fund (CDF) together with wider changes in the way the National Institute for Health and Care Excellence (NICE) assesses cancer drugs has recently been launched. Developed through a partnership between National Health Service (NHS) England and NICE, the new CDF allows drugs which meet set criteria under a managed access agreement…

Details

NICE issues new draft guidelines for end of life care

The National Institute for Health and Care Excellence (NICE) has issued draft guidelines for consultation to improve the care of adults during the last few days of life. The guidelines are meant to replace the Liverpool Care Pathway which were phased out in 2014. Key recommendations highlight the importance of communication and shared decision-making involving…

Details

Publication of revised International Staging System for myeloma

The International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…

Details

Major milestone reached for Myeloma UK Clinical Trial Network with publication of data from MUK one

Data from MUK one, the first trial to be conducted through the Myeloma UK Clinical Trial Network (CTN) have been published in the British Journal of Haematology. MUK one, a Phase II multicentre, open label, randomised trial aimed to identify the optimal starting dose of bendamustine when given in combination with thalidomide and dexamethasone in relapsed…

Details

Results of Cancer Drugs Fund’s list reassessment announced

The results of a reassessment of the nationally approved list of drugs made available through the Cancer Drugs Fund (CDF) have been announced by NHS England. They confirm that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients; Revlimid as a second-line treatment, and Velcade® as treatment for multiply relapsed Velcade-naive patients will remain on the list whereas…

Details